<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196765</url>
  </required_header>
  <id_info>
    <org_study_id>NV1205-009</org_study_id>
    <nct_id>NCT03196765</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy</brief_title>
  <official_title>Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroVia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroVia, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II, open label dose escalation study of multiple dose levels of NV1205 with
      a long-term treatment phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to evaluate the safety, pharmacokinetics, and efficacy of NV1205 in pediatric
      patients diagnosed with childhood cerebral adrenoleukodystrophy (CCALD).

      The study consists of:

        -  Screening period: within 30 days of first dose

        -  Main treatment period of 12 weeks (Part 1- from Screening to Week 12)

        -  Long Term Treatment (LTT) period (Part 2- Week 13 through Week 96)

      In Part 1, subjects will have an initial 4-week treatment period at the assigned dose and, if
      no safety concerns are noted, subjects continue for another 8 weeks of extended safety
      assessment.

      There will be several cohorts of subjects enrolled. After each Cohort has completed the
      4-week initial safety assessment, the safety data will be reviewed by an independent Data
      Safety Monitoring Board (DSMB) and, subject to DSMB recommendation, Cohort 2 will be enrolled
      and receive the next dose level. After Cohort 2 has completed 4 weeks of treatment, the DSMB
      will review all available safety data (Cohorts 1 and 2) and, subject to DSMB recommendation,
      Cohort 3 will be enrolled and receive the next dose level. Additional Cohorts may be enrolled
      at the recommendation of the DSMB with an incremental dose increase.

      In Part 2, subjects will continue to receive treatment in the LTT period of the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve concentration of NV1205 in plasma</measure>
    <time_frame>12 weeks</time_frame>
    <description>A sparse sampling approach will be utilized to estimate a 24-hr area under the curve of NV1205 plasma concentration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Loes score</measure>
    <time_frame>2 years</time_frame>
    <description>Percent change from baseline in brain lesions assessed as Loes score will be calculated</description>
  </other_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>X-Linked Adrenoleukodystrophy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sobetirome (NV1205)</intervention_name>
    <description>Once a day oral dose of the study drug</description>
    <other_name>NV1205</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males ≥4 years and &lt;18 years of age

          2. CCALD diagnosis confirmed by genetic testing

          3. Loes score of &gt;0 and ≤15

          4. Patients on VLCFA lowering agents such as Lorenzo's oil must stop the medication and
             have high VLCFA levels before enrollment

        Exclusion Criteria:

          -  Significant medical conditions such as heart, thyroid, or liver disease

          -  HSCT recipients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masoud Mokhtarani, MD</last_name>
    <role>Study Director</role>
    <affiliation>NeuroVia, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Program Director</last_name>
    <phone>415-870-6967</phone>
    <email>patients@neurovia-inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Austral</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de ninos Pedro de Elizalde</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Fahey, M.D.</last_name>
      <phone>(03) 8572 3757</phone>
      <email>michael.fahey@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Borja Arriarán</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Ninos</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardioinfantil</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre - Paris Sud</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endocrinology Research Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moscow Morozov`s Children Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Pediatric Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Children's Specialized Hospital 'OKHMATDET'</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>X-ALD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

